Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tamsulosin,Tadalafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akums Introduces Tamsulosin + Tadalafil Capsule — to the Indian Market
Details : DCGI has approved Tamsulosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil, a fixed dose combination within a hard gelatin capsule for the treatment of erectile dysfunction & benign prostatic hyperplasia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 15, 2023
Lead Product(s) : Tamsulosin,Tadalafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Adamed Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe
Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.
Brand Name : Vesomni-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 23, 2023
Lead Product(s) : Solifenacin Succinate,Tamsulosin
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Adamed Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tamsulosin,Solifenacin Succinate
Therapeutic Area : Urology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CDSCO Panel Gives Nod for FDC Tamsulosin + Solifenacin
Details : Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2022
Lead Product(s) : Tamsulosin,Solifenacin Succinate
Therapeutic Area : Urology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?